Hema Now | Episode 9
This week, Jonathan is joined by Anna Sureda, Head of the Clinical Hematology Department at Institut Català d’Oncologia – Hospital Duran i Reynals, Barcelona, Spain, and President of the European Society for Blood and Marrow Transplantation (EBMT), to discuss the latest in lymphoma therapies and stem cell transplantation.
Spotify | Apple | Amazon Music | YouTube | Download MP3 (49 mins)
Anna Sureda
Sureda is Head of the Clinical Hematology Department at the Institut Català d’Oncologia – Hospital Duran i Reynals, Barcelona, Spain.
With an extensive background in hematology, she has served as Senior Consultant at both Hospital de la Santa Creu i Sant Pau in Barcelona and Addenbrookes Hospital, Cambridge University Hospital in the UK, where she specialised in lymphomas and hematopoietic stem cell transplantation.
Throughout her career, Anna has focused on clinical investigations in the treatment of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and multiple myeloma, evaluating novel therapies such as immunotherapy combined with stem cell transplantation. She has held significant leadership roles and is currently President of the European Society for Blood and Marrow Transplantation (EBMT).
00:00 – Introduction
01:48 – Memorable travels
07:44 – Sureda’s journey into hematology
12:40 – Breakthroughs in lymphoma treatment
17:54 – Advances in stem cell transplantation
20:26 – EBMT initiatives
29:17 – Allogeneic transplantation for T cell lymphomas
34:32 – Challenges in treatment accessibility
41:35 – How can we ensure health equity?
46:00 – Advice to young hematologists
47:40 – Sureda’s three wishes for healthcare
